Based on the earnings call transcript, I anticipate a neutral to slightly positive short-term impact on JNJ's stock price. While there are some headwinds like OTC remediation costs and pricing pressures, these are balanced by several positives: 1) Strong performance of new products like ZYTIGA ($200M in sales), 2) Management maintaining full-year guidance despite challenges, and 3) The pending Synthes acquisition appears on track. The overall tone was cautiously optimistic with good control over expenses and continued innovation offsetting macro pressures.

[0]